News & Updates

Show Multimedia Only

Baricitinib cuts need for oral steroids in polymyalgia rheumatica

28 Jan 2025

In the treatment of patients with polymyalgia rheumatica, the Janus kinase 1/2 inhibitor baricitinib helps reduce the need to take oral glucocorticoids to have low disease activity while having no new safety signals, according to data from the randomized, double-blind BACHELOR trial.

Baricitinib cuts need for oral steroids in polymyalgia rheumatica

28 Jan 2025

Bimekizumab eases pain, morning stiffness in axSpA patients

27 Jan 2025 by

Treatment with bimekizumab quickly relieves pain and morning stiffness among patients with axial spondyloarthritis (axSpA), as shown in a study. Such improvements persist through week 52.

Bimekizumab eases pain, morning stiffness in axSpA patients

27 Jan 2025

High-dose folic acid use ups risk of malignancy in women with childbirth experience

27 Jan 2025

A recent study suggests that the use of high-dose folic acid may predispose parous women, including those with epilepsy, to cancer.

High-dose folic acid use ups risk of malignancy in women with childbirth experience

27 Jan 2025

Infliximab does not help with chronic low back pain-related disability

26 Jan 2025

In the treatment of patients with moderate-to-severe chronic low back pain, the use of infliximab does not yield meaningful reductions in pain-related disability when compared with placebo, as shown in a study.

Infliximab does not help with chronic low back pain-related disability

26 Jan 2025

No real-world evidence of montelukast link to neuropsychiatric adverse events in kids

25 Jan 2025 by

The use of montelukast in children treated in routine practice does not appear to pose any risks of neuropsychiatric events such as anxiety, depression, and sleep-related disorders, among others.

No real-world evidence of montelukast link to neuropsychiatric adverse events in kids

25 Jan 2025

Experimental drug for IBS falls flat in dose-ranging trial

25 Jan 2025

The novel α2δ ligand PD-217,014 does not appear to show any benefit in the treatment of patients with irritable bowel syndrome (IBS) or bowel habit subtypes, irrespective of their pain and anxiety levels, according to a study.

Experimental drug for IBS falls flat in dose-ranging trial

25 Jan 2025

Postexposure doxycycline brings down STI rates among people on PrEP

24 Jan 2025 by

Individuals already taking pre-exposure prophylaxis (PrEP) for HIV prevention saw sharp declines in chlamydia and syphilis cases, as well as a moderate reduction in urethral and rectal gonorrhoea, when they also took doxycycline after potential exposure (doxyPEP).

Postexposure doxycycline brings down STI rates among people on PrEP

24 Jan 2025

Evidence-based strategies to optimise the management of respiratory diseases

24 Jan 2025

On 9 November 2024, GSK organised the 2024 Respiratory Summit: Breath Easy, Live Fully under the auspices of the Singapore Thoracic Society. The summit featured presentations from esteemed experts, Dr Chew Si Yuan and Dr Steve Yang, who discussed recent updates to the guidelines for respiratory diseases – such as chronic obstructive pulmonary disease (COPD), asthma and respiratory syncytial virus (RSV) infections – and strategies to optimise patient outcomes. The session was chaired by Dr Jim Teo.

Evidence-based strategies to optimise the management of respiratory diseases

24 Jan 2025

Isotretinoin for acne: Higher total dose exposure, lower relapse risk?

23 Jan 2025 by

A large cohort study suggests that for patients with acne who received an isotretinoin treatment course, the cumulative dosage taken, rather than the daily dose, is a key factor for reducing the risk of relapse and treatment retrial.

Isotretinoin for acne: Higher total dose exposure, lower relapse risk?

23 Jan 2025

Immune thrombocytopenia in infants usually mild, self-limiting

23 Jan 2025 by

Parents of infants with immune thrombocytopenia (ITP) need not worry too much as the disease is almost always self-limiting and transient, with most cases not requiring treatment, suggests a Singapore study. In addition, chances of developing chronic ITP are slim.

Immune thrombocytopenia in infants usually mild, self-limiting

23 Jan 2025

News & Updates

Filter by Specialty:

Specialty:

Baricitinib cuts need for oral steroids in polymyalgia rheumatica

Baricitinib cuts need for oral steroids in polymyalgia rheumatica

Bimekizumab eases pain, morning stiffness in axSpA patients

Bimekizumab eases pain, morning stiffness in axSpA patients

High-dose folic acid use ups risk of malignancy in women with childbirth experience

High-dose folic acid use ups risk of malignancy in women with childbirth experience

Infliximab does not help with chronic low back pain-related disability

Infliximab does not help with chronic low back pain-related disability

No real-world evidence of montelukast link to neuropsychiatric adverse events in kids

No real-world evidence of montelukast link to neuropsychiatric adverse events in kids

Experimental drug for IBS falls flat in dose-ranging trial

Experimental drug for IBS falls flat in dose-ranging trial

Postexposure doxycycline brings down STI rates among people on PrEP

Postexposure doxycycline brings down STI rates among people on PrEP

Evidence-based strategies to optimise the management of respiratory diseases

Evidence-based strategies to optimise the management of respiratory diseases

Isotretinoin for acne: Higher total dose exposure, lower relapse risk?

Isotretinoin for acne: Higher total dose exposure, lower relapse risk?

Immune thrombocytopenia in infants usually mild, self-limiting

Immune thrombocytopenia in infants usually mild, self-limiting